BioSIM 抗人 P-selectin/CD62 抗体 (立赞利珠单抗),生物类似药 5mg
文献支持

BioSIM 抗人 P-selectin/CD62 抗体 (

立赞利珠单抗),生物类似药 5mg
收藏
  • 询价
  • InvivoCrown
  • 英国
  • SIM0220-5mg
  • 2025年11月10日
  • ELISA, FACS, Functional assay, Research in vivo
  • Humanized
  • Human
  • 详细信息
  • 文献和实验
  • 技术资料
  • 免疫原

    该BioSIM 抗人 P-selectin/CD62 抗体 (立赞利珠单抗),生物类似药,科研用途 [ CAS: 1690318-25-2]的免疫原请参考该产品的说明书

  • 保存条件

    为确保适当储存,请避免反复冻融。短期需求(1-2周)请在4°C下保存;最长12个月的储存请在-20°C下保存。长期储存请在-80°C下保存。

  • 克隆性

    单克隆

  • 适应物种

    Human

  • 保质期

    为确保适当储存,请避免反复冻融。短期需求(1-2周)请在4°C下保存;最长12个月的储存请在-20°C下保存。长期储存请在-80°C下保存。

  • 级别

    科研级别

  • 库存

    999

  • 供应商

    亚科因(Abbkine)

  • 宿主

    Humanized

  • 应用范围

    ELISA, FACS, Functional assay, Research in vivo

  • 抗体英文名

    P-selectin/CD62

  • 抗体名

    P-selectin/CD62

  • 规格

    5mg

BioSIM 抗人 P-selectin/CD62 抗体(立赞利珠单抗生物类似药)- 科研级

英文名称:BioSIM anti-Human P-selectin/CD62 Antibody (Crizanlizumab Biosimilar), Research Grade

产品货号:SIM0220-5mg | 产品规格:5mg

核心产品参数

  • 产品类型:二抗
  • 来源宿主:Humanized(人源化)
  • 反应性:Human(人源)
  • CAS号:1690318-25-2
  • 科研聚焦领域:镰状细胞血症

背景与生产工艺

本产品为立赞利珠单抗(Crizanlizumab)的生物类似药,属于科研级重组抗体,生产全程遵循标准化流程:

  • 生产设施无动物成分,避免外源性动物源污染物对实验的干扰
  • 采用体外无蛋白细胞培养技术,减少非目标蛋白残留
  • 经多步骤纯化工艺,包含Protein A或G色谱核心步骤,保障抗体纯度与特异性

针对镰状细胞血症研究需求设计,为相关机制探索提供靶向工具。

适用科研应用

可支持以下实验方向:

  • ELISA:抗原-抗体特异性结合检测
  • FACS:细胞表面P-selectin/CD62标志物定量分析
  • Functional assay:抗体功能活性验证(如细胞黏附抑制等)
  • Research in vivo:体内机制研究(需结合实验体系验证适用性)

注:免疫原具体信息请参考产品配套说明书。

保存与稳定性建议

为维持抗体活性,需严格遵循储存条件:

  • 短期使用(1-2周内):4°C避光保存(避免反复开盖)
  • 中期储存(最长12个月):-20°C避光保存(建议密封防污染)
  • 长期储存:-80°C避光保存(推荐分装为小体积,减少冻融次数)

重要提示:反复冻融会导致抗体活性下降,实验前需确认储存状态。

供应商信息

供应商:InvivoCrown

注意:以上信息可能随着产品优化升级等因素产生变动,具体信息请咨询亚科因公司。

亚科因(Abbkine)

BioSIM Anti-Human P-selectin/CD62 Antibody (Crizanlizumab Biosimilar) - Research Grade

Product Cat. No.: SIM0220-5mg | Product Specification: 5mg

Core Product Parameters

  • Product Type: Secondary Antibody
  • Host Source: Humanized
  • Reactivity: Human
  • CAS No.: 1690318-25-2
  • Research Focus Area: Sickle Cell Disease

Background and Production Process

This product is a biosimilar of Crizanlizumab, belonging to research-grade recombinant antibodies. The entire production process follows standardized procedures:

  • The production facility is animal-component-free to avoid interference from exogenous animal-derived contaminants in experiments
  • Adopts protein-free in vitro cell culture technology to reduce non-target protein residues
  • Undergoes a multi-step purification process, including core steps of Protein A or G chromatography, to ensure antibody purity and specificity

Designed for the research needs of sickle cell disease, providing a targeted tool for exploring related mechanisms.

Applicable Research Applications

Can support the following experimental directions:

  • ELISA: Antigen-antibody specific binding assay
  • FACS: Quantitative analysis of cell surface P-selectin/CD62 markers
  • Functional assay: Verification of antibody functional activity (e.g., cell adhesion inhibition, etc.)
  • In vivo research: In vivo mechanism study (applicability needs to be verified in combination with experimental systems)

Note: For specific information about the immunogen, please refer to the product's accompanying manual.

Storage and Stability Recommendations

To maintain antibody activity, strict adherence to storage conditions is required:

  • Short-term use (within 1-2 weeks): Store at 4°C away from light (avoid repeated opening)
  • Medium-term storage (up to 12 months): Store at -20°C away from light (seal recommended to prevent contamination)
  • Long-term storage: Store at -80°C away from light (aliquot into small volumes recommended to reduce freeze-thaw cycles)

Important Note: Repeated freeze-thaw cycles will cause a decrease in antibody activity. Please confirm the storage status before experiments.

Supplier Information

Supplier: InvivoCrown

Note: The above information may change due to factors such as product optimization and upgrading. For specific information, please consult InvivoCrown.

风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。

图标文献和实验
该产品被引用文献
BioSIM anti-Human P-selectin/CD62 Antibody (Crizanlizumab Biosimilar), Research Grade
图标技术资料

暂无技术资料 索取技术资料

同类产品报价

产品名称
产品价格
公司名称
报价日期
询价
亚科因(武汉)生物技术有限公司
2025年11月10日询价
¥180
北京博奥森生物技术有限公司
2025年10月10日询价
文献支持
BioSIM 抗人 P-selectin/CD62 抗体 (立赞利珠单抗),生物类似药 5mg
询价